# Antimicrobial Stewardship in Respiratory Infections of Dogs and Cats


## Key Takeaways

- Respiratory infections in dogs and cats are frequently viral, with bacterial superinfection occurring in a minority of cases; therefore, antimicrobial therapy should only be initiated when a bacterial threshold is met, evidenced by criteria such as fever >39.5°C, mucopurulent discharge with cytology, or alveolar radiographic patterns.
- Diagnostic reasoning is paramount, involving signalment, physical examination (fever, tachypnea, adventitious lung sounds), and targeted testing such as thoracic radiographs; deep airway sampling (transtracheal wash, BAL) for cytology and culture is indicated for suspected pneumonia before initiating antimicrobials to guide therapy.
- First-line antimicrobial choices for bacterial respiratory infections include amoxicillin-clavulanate or doxycycline, prioritizing narrow-spectrum agents to preserve critically important antimicrobials.
- Highest priority critically important antimicrobials, such as fluoroquinolones and third-generation cephalosporins, should be reserved for confirmed resistance to first-line agents, severe life-threatening infections, or specific pathogens where no alternatives exist, not for convenience or mild disease.
- Antimicrobial therapy duration for uncomplicated bacterial pneumonia should typically be 7 to 10 days, with clinical resolution, not radiographic clearing alone, serving as the primary endpoint for discontinuation.
- Species-specific considerations are crucial; in cats, the difficulty of oral medication can lead to the use of injectables like cefovecin, but this should be carefully weighed against its status as a critically important antimicrobial and alternative strategies explored.

---

Respiratory tract infections are among the most common indications for antimicrobial prescribing in small animal practice, yet many of these infections resolve without antibiotic intervention. This article provides a diagnostic reasoning framework for the practicing veterinarian, distinguishing bacterial infections that require antimicrobial therapy from viral, inflammatory, and noninfectious conditions that do not. It addresses drug selection, duration of therapy, and stewardship principles specific to canine and feline respiratory disease, with emphasis on avoiding highest priority critically important antimicrobials where effective alternatives exist. Chronic bronchitis is excluded from this discussion.

The clinical question at the center of this article is practical: when a dog or cat presents with coughing, nasal discharge, or fever, how does the clinician determine whether bacteria are the problem, which antimicrobial is appropriate if they are, and when can treatment be safely withheld? The answers draw on published prescribing data, consensus guidelines, and the pharmacology of commonly used respiratory antimicrobials. The goal is not to eliminate antibiotic use but to align it with demonstrable need.

## At a Glance

| Parameter | Clinical Decision Point |
|---|---|
| Acute canine cough with mild signs | Supportive care, no antimicrobials, reassess in 7 to 10 days |
| Feline acute upper respiratory tract disease | Antimicrobials only if mucopurulent discharge, fever, or suspected secondary bacterial infection |
| Canine community-acquired pneumonia | Antimicrobials indicated, amoxicillin-clavulanate or doxycycline as first-line options |
| Feline bronchopneumonia | Antimicrobials indicated, doxycycline or amoxicillin-clavulanate preferred |
| Cytology or culture indication | Deep airway sampling before antimicrobial initiation when pneumonia is suspected |
| Duration of therapy | Treat 7 to 10 days for uncomplicated infections, extend based on clinical resolution, not radiographs alone |
| Highest priority critically important antimicrobials | Reserve fluoroquinolones and third-generation cephalosporins for confirmed resistance or severe disease |
| Stewardship tools | Online prescribing aids and practice-level audits reduce inappropriate antimicrobial use |

## Why Antimicrobial Stewardship Matters in Respiratory Disease

Respiratory infections in dogs and cats are predominantly viral in origin. Feline herpesvirus, calicivirus, and a range of canine respiratory viruses produce clinical signs that mimic bacterial infection, and secondary bacterial invasion occurs in a minority of cases. Despite this, prescribing surveys consistently show high rates of antimicrobial use for these conditions. In a Swiss study of feline acute upper respiratory tract disease, 77% of 227 cases received antibiotic therapy, yet only a fraction of those prescriptions were judged fully compliant with consensus guidelines. Similar patterns appear in canine respiratory tract infection data, where antimicrobial prescribing decreased from 74% to 59% after introduction of a stewardship tool, indicating both the scale of overprescribing and the potential for improvement.

The consequences of unnecessary prescribing extend beyond individual patients. Antimicrobial resistance in respiratory pathogens is driven by cumulative drug exposure at the population level. The World Organization for Animal Health maintains international standards for antimicrobial use that emphasize responsible prescribing as a component of animal health and welfare [WOAH terrestrial animal health code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). Professional bodies such as the American Veterinary Medical Association similarly frame antimicrobial stewardship as a core clinical responsibility, not an administrative afterthought [AVMA antimicrobial use and stewardship guidance](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance).

## Pathophysiology of Respiratory Infection and the Bacterial Threshold

The respiratory tract possesses multilayered defenses: mucociliary clearance, secretory immunoglobulins, alveolar macrophages, and a resident microbiome that competes with pathogens. Bacterial pneumonia develops when these defenses are overwhelmed, either by high pathogen load, impaired clearance, or immune compromise. Viral infection is the most common predisposing factor, damaging ciliated epithelium and allowing bacterial adherence and proliferation.

The concept of a bacterial threshold is central to stewardship reasoning. In viral upper respiratory infection, bacterial numbers remain low and the immune response clears them without antimicrobial assistance. In bacterial pneumonia, organizms such as *Bordetella bronchiseptica*, *Streptococcus* species, *Escherichia coli*, and anaerobes proliferate within the lower airways, producing fever, lethargy, and radiographic consolidation. The clinician's task is to identify which patients have crossed this threshold.

Clinical signs that shift the probability toward bacterial infection include mucopurulent nasal discharge, fever exceeding 39.5°C, lethargy, anorexia, and abnormal lung sounds. However, these signs are neither perfectly sensitive nor specific. A cat with viral rhinotracheitis can develop purulent nasal discharge from neutrophilic inflammation alone, without bacterial infection. Conversely, early bacterial pneumonia may present with only mild cough and tachypnea. This uncertainty is why diagnostic testing, not empiric prescribing, is the foundation of stewardship.

## Diagnostic Reasoning: Distinguishing Bacterial From Nonbacterial Disease

### Signalment and Exposure History

Age, vaccination status, and environment provide the first layer of diagnostic discrimination. Young kittens from shelters have a high pretest probability of viral upper respiratory infection. Adult dogs with acute onset cough and a history of recent boarding or kennel exposure are likely to have infectious tracheobronchitis, which is viral or *Bordetella* associated and frequently self-limiting. Older animals with chronic cough and no systemic signs are more likely to have airway collapse, cardiac disease, or neoplasia than primary bacterial infection.

### Physical Examination Findings

The presence of fever, tachypnea, increased respiratory effort, and auscultable crackles or wheezes supports lower airway involvement. Nasal discharge that is unilateral, malodorous, or associated with facial deformity suggests fungal infection or foreign body instead of primary bacterial rhinitis. Thoracic auscultation in cats is often unrewarding due to small thoracic volume and rapid respiratory rate, so the absence of abnormal lung sounds does not exclude pneumonia.

### Diagnostic Testing Strategy

For patients with suspected bacterial pneumonia, thoracic radiographs are the first-line imaging modality. Alveolar patterns with air bronchograms in the dependent lung lobes support a diagnosis of pneumonia, though viral pneumonitis can produce similar findings. For upper respiratory disease, radiographs are less helpful unless dental disease, nasal foreign body, or neoplasia is suspected.

Cytology and culture from deep airway samples provide the definitive diagnosis. Transtracheal wash, endotracheal wash, or bronchoalveolar lavage should be performed before antimicrobial initiation whenever pneumonia is suspected and the patient is stable enough to tolerate the procedure. Culture results guide drug selection and allow de-escalation from broad-spectrum empiric therapy. The MSD Veterinary Manual provides detailed procedural guidance for airway sampling techniques [MSD Veterinary Manual professional respiratory diagnostics](https://www.msdvetmanual.com/).

### The Role of Point-of-Care Testing

Acute phase proteins such as serum amyloid A and C-reactive protein have been evaluated as markers of bacterial infection, but their sensitivity and specificity are insufficient to rule in or rule out bacterial pneumonia in individual patients. Feline leukemia virus and feline immunodeficiency virus testing is appropriate in cats with recurrent or severe respiratory infections, as retroviral status influences prognosis and management. Polymerase chain reaction panels for respiratory pathogens can identify viral etiologies, but a positive result does not confirm bacterial infection and should not trigger antimicrobial prescribing on its own.

## Antimicrobial Selection Principles

### First-Line Agents

When antimicrobial therapy is indicated, the choice should reflect the most likely pathogens, tissue penetration, and the stewardship principle of using the narrowest effective agent. For canine pneumonia, amoxicillin-clavulanate provides coverage against *Streptococcus*, *Pasteurella*, and anaerobes, with reasonable activity against *Bordetella*. Doxycycline is preferred when *Mycoplasma* or *Bordetella* is suspected, and it achieves excellent concentrations in respiratory tissues. For feline upper respiratory infection with suspected secondary bacterial involvement, doxycycline is often the first choice due to activity against *Chlamydia felis*, *Mycoplasma*, and *Bordetella*.

### Avoiding Highest Priority Critically Important Antimicrobials

Fluoroquinolones and third-generation cephalosporins are classified as highest priority critically important antimicrobials by the World Health Organization. Their use in veterinary medicine should be reserved for cases with confirmed resistance to first-line agents, severe life-threatening infection, or specific pathogens for which alternatives do not exist [Lhermie et al. on indications for highest priority critically important antimicrobials](https://pubmed.ncbi.nlm.nih.gov/32240295/). Cefovecin, a third-generation cephalosporin, is frequently prescribed in feline practice for convenience, particularly when oral medication is difficult. Electronic health record data from UK first-opinion practices show that respiratory conditions account for approximately 10% of cefovecin use, and inability to orally medicate the cat is the most commonly cited reason [Burke et al. on cefovecin use in UK cats](https://pubmed.ncbi.nlm.nih.gov/27507842/). While this rationale is understandable, it does not justify the use of a highest priority antimicrobial when oral doxycycline or amoxicillin-clavulanate could be administered with owner commitment or when the infection may not require antimicrobials at all.

### Duration of Therapy

Short courses are preferred. For uncomplicated bacterial pneumonia, 7 to 10 days of treatment is typically sufficient, with reassessment at the end of the course. Clinical resolution, defined as return to normal appetite, activity, and respiratory rate, is a better endpoint than radiographic clearing, which lags behind clinical improvement by weeks. Extended courses beyond 14 days are rarely necessary and increase selection pressure for resistant organizms.

## Clinical Decision Algorithm for Respiratory Infection Management

The diagnostic sequence for respiratory infections follows a structured pathway that begins with triage and ends with a treatment decision. Each step carries explicit exit points where antimicrobial therapy becomes justified or where further diagnostics are required before prescribing.

### Step 1: Triage and Stabilization

Assess perfusion, oxygenation, and respiratory effort before any diagnostic testing. Patients with cyanosis, severe tachypnoea, or evidence of upper airway obstruction require oxygen supplementation and stabilization before sample collection. Thoracic radiographs should not be deferred in dyspnoeic patients once stabilized, as the distinction between bronchial, interstitial, alveolar, and pleural patterns changes both the differential list and the antimicrobial decision.

### Step 2: Classification by Anatomical Site

Localize the infection to the upper respiratory tract (nasal cavity, pharynx, larynx, trachea) or lower respiratory tract (bronchi, bronchioles, pulmonary parenchyma). This classification determines which samples are obtainable, which pathogens are likely, and whether empirical therapy is ever appropriate. Upper respiratory disease in cats is predominantly viral in origin, and antimicrobial prescription rates of 77% in one Swiss study of acute upper respiratory tract disease exceeded what the evidence supports [antimicrobial use for selected diseases in cats in Switzerland](https://pubmed.ncbi.nlm.nih.gov/30871537/).

### Step 3: Apply the Bacterial Threshold Criteria

Antimicrobial therapy is indicated when one or more of the following criteria are met:

- Purulent nasal discharge with cytological evidence of septic suppurative inflammation
- Fever exceeding 39.5°C with localizing respiratory signs and no other source
- Alveolar pattern on thoracic radiographs with compatible clinical signs
- Neutrophilia with left shift on hematology
- Known exposure to a bacterial pathogen with high morbidity
- Progressive clinical deterioration despite supportive care

The absence of these criteria favours viral, allergic, or inflammatory disease. In dogs with respiratory tract infection, antimicrobial prescription rates decreased from 74% to 59% after introduction of a stewardship tool, demonstrating that a substantial proportion of prescriptions can be safely avoided [effect of antimicrobial stewardship on antimicrobial prescriptions for selected diseases of dogs in Switzerland](https://pubmed.ncbi.nlm.nih.gov/33112451/).

### Step 4: Sample Collection Before Therapy

When antimicrobial therapy is indicated, collect samples before administration whenever feasible. Nasal swabs for cytology and culture, transtracheal wash, or bronchoalveolar lavage provide cytological confirmation and culture guidance. Blood cultures are underused in febrile pneumonia patients and should be considered when sepsis is suspected. If sampling is not possible, document the reason and proceed with empirical therapy based on the most likely pathogen.

### Step 5: Select Therapy and Define the Review Point

Choose the antimicrobial class based on the first-line agent table below, the patient's ability to tolerate oral medication, and the severity of disease. Define a re-examination time point before dispensing the medication. For mild disease, this is typically 48 to 72 hours. For moderate to severe disease, re-evaluation at 24 to 48 hours is appropriate. The owner should understand that the antimicrobial may be discontinued if the clinical picture changes or culture results indicate a narrower agent.

### Step 6: Reassess and Adjust

At the review point, repeat the bacterial threshold assessment. Clinical improvement with negative bacterial criteria supports discontinuation of therapy. Lack of improvement requires re-evaluation of the diagnosis, consideration of resistance, and review of culture results if samples were obtained. A switch to a broader agent without culture support is rarely justified and should prompt referral or advanced diagnostics.

## First-Line Antimicrobial Selection

The table below summarizes first-line choices for common respiratory infection scenarios. Current formulary and label references must be consulted for doses, contraindications, and withdrawal periods.

| Clinical Scenario | First-Line Agent Class | Rationale | Alternative if Oral Medication Impossible |
|---|---|---|---|
| Feline acute upper respiratory disease with confirmed bacterial component | Amoxicillin or amoxicillin-clavulanate | Narrow spectrum, covers common feline respiratory bacteria | Cefovecin, noting that respiratory use is common but frequently off-label [use of cefovecin in a UK population of cats](https://pubmed.ncbi.nlm.nih.gov/27507842/) |
| Canine infectious tracheobronchitis with bacterial superinfection | Doxycycline | Covers Bordetella bronchiseptica and Mycoplasma species | Doxycycline injectable formulation |
| Canine community-acquired pneumonia, mild to moderate | Amoxicillin-clavulanate | Covers common canine respiratory pathogens | Ampicillin-sulbactam injectable |
| Feline bronchopneumonia, mild to moderate | Amoxicillin-clavulanate | Broad enough for common feline isolates | Cefovecin with documented rationale |
| Severe or hospital-acquired pneumonia | Culture-guided therapy, pending results, consider combination therapy | Empirical broad-spectrum cover is justified only in severe disease | Parenteral therapy with monitoring |

Third-generation cephalosporins and fluoroquinolones are reserved for culture-confirmed resistance or severe disease where no effective alternative exists. These agents are classified as highest priority critically important antimicrobials, and their use in companion animals should be justified and documented [indications for the use of highest priority critically important antimicrobials in the veterinary sector](https://pubmed.ncbi.nlm.nih.gov/32240295/).

## Monitoring Plan and Parameters

Monitoring serves three purposes: confirming clinical response, detecting adverse effects, and determining the appropriate duration of therapy. The parameters below should be assessed at each re-examination.

| Monitoring Parameter | Frequency | What It Detects | Action if Abnormal |
|---|---|---|---|
| Respiratory rate and effort | Daily during acute phase | Progression or resolution of disease | Worsening requires re-imaging and culture review |
| Rectal temperature | Daily during acute phase | Persistent infection or drug fever | Persistent fever beyond 72 hours warrants re-evaluation |
| Appetite and demeanour | Daily | Systemic response to therapy | Poor appetite may indicate inadequate response or drug intolerance |
| Thoracic auscultation | Every 48 to 72 hours | Resolution of crackles or wheezes | Persistent adventitious sounds warrant repeat radiographs |
| Thoracic radiographs | At 7 to 14 days for pneumonia | Radiographic resolution lags clinical improvement | Persistent alveolar pattern without clinical signs does not mandate continued therapy |
| Mucous membrane color and perfusion | Daily during acute phase | Sepsis or cardiovascular compromise | Immediate re-stabilization required |
| Gastrointestinal signs | Daily | Antimicrobial-associated diarrhea or vomiting | Consider probiotic support or agent change |

Clinical improvement typically precedes radiographic resolution by several days. Radiographic persistence alone should not extend antimicrobial therapy if the patient is clinically normal. Conversely, clinical deterioration while on appropriate therapy warrants immediate investigation for complications such as abscessation, foreign body, or neoplasia.

## Documentation and Stewardship Recording

Every antimicrobial prescription for a respiratory infection should be documented with the indication, the bacterial threshold criteria met, the agent selected, the dose and duration, and the planned review date. This documentation serves clinical continuity and provides the data needed for practice-level stewardship audits. The introduction of structured stewardship tools has been associated with measurable reductions in antimicrobial prescribing in companion animal practice [antimicrobial prescriptions in cats in Switzerland before and after the introduction of an online antimicrobial stewardship tool](https://pubmed.ncbi.nlm.nih.gov/32620170/). Practices should review their own prescribing patterns periodically and compare them with published benchmarks.

## Species-Specific Considerations

Feline patients present distinct challenges. Oral medication is frequently difficult, which drives the use of long-acting injectable agents such as cefovecin. However, the convenience of these agents must be weighed against their spectrum and their status as highest priority critically important antimicrobials. In one UK study, the most cited reason for cefovecin use was an inability to orally medicate the cat [use of cefovecin in a UK population of cats](https://pubmed.ncbi.nlm.nih.gov/27507842/). This rationale should be documented explicitly, and alternative strategies such as compounded liquid formulations or hospitalization for parenteral therapy should be considered first.

Canine patients more commonly tolerate oral medication, which expands the first-line options. Doxycycline is well tolerated in dogs when administered with food and is the preferred agent for suspected Bordetella or Mycoplasma infection. The risk of esophageal stricture with doxycycline tablets in cats is well recognized, and tablets should be followed by a water flush or liquid formulations used.

## When to Refer or Hospitalize

Hospitalization is indicated for patients with moderate to severe pneumonia, suspected sepsis, hypoxemia, or an inability to maintain hydration or nutrition. Referral should be considered when the patient fails to respond to appropriate first-line therapy within 72 hours, when culture results indicate resistance to all oral options, or when advanced diagnostics such as bronchoscopy or computed tomography are required to characterize the disease. The decision to escalate therapy should never be made without first questioning the diagnosis.

## Recognized Complications and Failure Modes

The most common failure in managing respiratory infections is not a drug error but a diagnostic one: treating a viral, allergic, or inflammatory process with antimicrobials when the bacterial threshold has not been met. This error is detectable early when the clinician reviews the case at the 48 to 72 hour reassessment point. If the patient has not deteriorated and the original criteria for bacterial infection were weak, the correct action is to stop therapy instead of extend it. A second failure mode is selecting a broad-spectrum agent when a narrow first-line drug would suffice. Prescribing a third-generation cephalosporin or a fluoroquinolone for uncomplicated canine infectious tracheobronchitis is a common example, and it directly contradicts stewardship principles outlined in professional guidance on [judicious antimicrobial use and resistance mitigation](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance).

A third failure is the assumption that clinical deterioration after 48 hours of therapy indicates antimicrobial resistance. More often it indicates an incorrect diagnosis, a noninfectious complication such as aspiration or neoplasia, or a drug that cannot penetrate the target site. The discriminating check is to revisit the diagnostic plan, obtain or review thoracic radiographs, and consider sampling for cytology and culture before changing drugs. A fourth failure mode is the reflexive use of a long-acting injectable antimicrobial to solve a compliance problem. In one UK electronic health record study, inability to orally medicate the cat was the most cited reason for choosing cefovecin, and respiratory disease accounted for a substantial share of those prescriptions. That rationale addresses owner convenience, not patient need, and it removes the opportunity for early reassessment and dose adjustment. The [recorded use of cefovecin in first-opinion feline practice](https://pubmed.ncbi.nlm.nih.gov/27507842/) illustrates how stewardship can be compromised by practical pressures.

| Observation | Likely cause | Discriminating check |
| --- | --- | --- |
| Fever persists beyond 48 hours of appropriate therapy | Wrong diagnosis, noninfectious inflammation, or drug penetration failure | Repeat physical examination, thoracic radiographs, cytology and culture |
| Clinical signs improve but cough persists for weeks | Postinfectious airway inflammation or residual damage | Recheck at 2 weeks, reserve antimicrobials for new fever or purulent nasal discharge |
| Owner reports inability to give oral medication | Compliance barrier, not a bacterial indication | Consider oral suspension, compounded formulation, or hospitalization instead of a long-acting injectable |
| Purulent nasal discharge recurs after stopping therapy | Foreign body, dental disease, or fungal rhinitis | Nasal imaging, rhinoscopy, deep culture, histopathology |
| Radiographic infiltrates worsen despite treatment | Aspiration pneumonia, neoplasia, or cardiogenic edema | Re-evaluate radiographs, consider bronchoscopy with BAL, review history for vomiting or dysphagia |

## Common Errors and Corrective Action

Less experienced clinicians frequently prescribe antimicrobials for acute feline upper respiratory tract disease because ocular and nasal discharge looks purulent. Purulent appearance reflects neutrophil influx, which occurs in viral and caliciviral disease as readily as in bacterial infection. The corrective action is to apply the bacterial threshold criteria before prescribing. A Swiss study of antimicrobial use in cats with acute upper respiratory tract disease found that 77% of cases received antibiotics, yet only a minority of prescriptions were judged fully compliant with consensus guidelines. The [assessment of antimicrobial prescriptions in cats with respiratory disease](https://pubmed.ncbi.nlm.nih.gov/30871537/) shows that overprescription is measurable and correctable when clinicians apply explicit criteria.

Another common error is extending therapy because the owner expects a prescription refill. The corrective action is to document the reassessment findings and explain that the bacterial threshold has not been met. A related error is choosing a fluoroquinolone for a suspected Bordetella infection when doxycycline is the first-line agent. Fluoroquinolones are classified as highest priority critically important antimicrobials, and their use should be reserved for cases with culture confirmation, documented resistance, or a specific clinical rationale. The [review of indications for highest priority critically important antimicrobials in veterinary medicine](https://pubmed.ncbi.nlm.nih.gov/32240295/) identifies respiratory infections as a common indication across species, which makes deliberate avoidance of these drugs in routine canine and feline cases a priority.

## Limitations of the Evidence and Areas of Expert Disagreement

The evidence base for antimicrobial duration in canine and feline respiratory infections is thin. Most recommendations for 5 to 7 day courses derive from expert opinion and extrapolation from human medicine instead of randomised veterinary trials. Clinicians should treat duration as a starting point and use the reassessment examination to individualise therapy. Expert opinion also differs on the value of bacterial culture from the upper airway. Some specialists argue that culture of nasal swabs is unreliable because of commensal flora and contamination, while others use it selectively in chronic or recurrent cases. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on when culture is likely to change management, and clinicians should consult it when uncertainty arises.

There is also disagreement about the role of corticosteroids as adjunctive therapy in bacterial pneumonia. Some experts advocate their use to reduce airway inflammation, while others warn that they may impair bacterial clearance. The evidence is insufficient to resolve this question, and the decision should be made on a case-by-case basis with explicit documentation of the rationale.

## Referral, Consultation, and Regulatory Reporting

Referral is warranted when the patient fails to respond to appropriate first-line therapy, when diagnostic imaging or sampling is beyond the practice's capability, when the patient requires mechanical ventilation or continuous oxygen support, or when a zoonotic pathogen such as Bordetella bronchiseptica is suspected in a household with immunocompromised humans. Specialist consultation is appropriate for recurrent pneumonia, suspected fungal disease, or suspected foreign body aspiration. Laboratory involvement is indicated when culture and susceptibility testing will change therapy, particularly in cases of suspected resistance or in patients that have already received multiple antimicrobial courses.

Regulatory reporting obligations vary by jurisdiction. Clinicians should be aware that extralabel use of certain drugs, particularly fluoroquinolones and third-generation cephalosporins, may be restricted or require additional documentation. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) publishes current information on approved drugs, extralabel use policy, and adverse event reporting, and the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address international expectations for antimicrobial surveillance and reporting. Clinicians should consult their national veterinary body for jurisdiction-specific requirements.

## Frequently Asked Questions

**How do I manage a respiratory infection when cytology or culture is not available?**

When laboratory access is limited, base the bacterial threshold decision on physical examination, signalment, and imaging findings. Purulent nasal discharge with unilateral signs, lung consolidation on radiographs, toxic neutrophils on a Diff-Quik stained smear, or fever with lethargy support bacterial infection. If the patient is systemically well and discharge is serous or mucoid, defer antimicrobials and reassess in 48 to 72 hours. When you do prescribe, choose a first-line agent and document the clinical rationale. The Swiss stewardship experience shows that structured decision support reduces unnecessary prescribing even in first-opinion settings without advanced diagnostics, as reported in the [evaluation of an online antimicrobial stewardship tool in cats](https://pubmed.ncbi.nlm.nih.gov/32620170/).

**What should I do when a client refuses diagnostic testing but requests antibiotics?**

Explain that antibiotics treat bacterial infection, not viral shedding or inflammation, and that unnecessary use promotes resistance in their pet and household. Offer a compromise: a short review period with symptomatic care, then antimicrobials if the condition worsens or fails to improve. If the client insists on treatment, prescribe a first-line agent for the shortest reasonable course and schedule a mandatory recheck. Record the client's refusal of diagnostics and your discussion in the medical record. Professional guidance from the [AVMA on antimicrobial use and stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) supports this shared decision-making approach.

**How do I choose between oral and injectable antimicrobials when compliance is poor?**

Injectable options are attractive when owners cannot medicate orally, but they remove the ability to stop therapy early if adverse effects occur. Cefovecin is a third-generation cephalosporin and should be reserved for cases where oral administration is genuinely impossible and a bacterial infection is confirmed or strongly suspected. Electronic health record data from UK first-opinion practices show that inability to orally medicate is the most commonly cited reason for choosing cefovecin, yet respiratory indications accounted for only a small fraction of its use. Consider hospitalization for parenteral therapy with a narrower agent, or explore alternative formulations, before defaulting to a long-acting critically important antimicrobial. Consult current [FDA animal drug information](https://www.fda.gov/animal-veterinary) for approved indications and labeling.

**When is it appropriate to use a fluoroquinolone or third-generation cephalosporin in feline respiratory disease?**

These highest priority critically important antimicrobials are appropriate only when culture and susceptibility testing confirm a resistant pathogen, when the patient is deteriorating despite first-line therapy, or when a specific clinical syndrome such as neonatal pneumonia demands their use. A Swiss study of antimicrobial use in cats found that potentiated aminopenicillins and third-generation cephalosporins dominated prescriptions for acute upper respiratory tract disease, yet guideline compliance was low. The [review of highest priority critically important antimicrobial indications](https://pubmed.ncbi.nlm.nih.gov/32240295/) notes that effective oral alternatives are often lacking in cats, which argues for careful case selection instead of routine avoidance. Document the justification, the susceptibility result, and the planned review date whenever you use these agents.

**How should I document antimicrobial decisions to support stewardship auditing?**

Record the suspected or confirmed pathogen, the bacterial threshold criteria met, the drug chosen, the dose, the planned duration, and the specific review point. Note any culture results, imaging findings, or cytology that informed the decision. If you deferred antimicrobials, record that decision and the owner's understanding. If you used a highest priority critically important drug, document the reason and the alternative considered. This record supports recheck decisions and protects against criticism during regulatory inspection. The [Swiss canine stewardship study](https://pubmed.ncbi.nlm.nih.gov/33112451/) demonstrated that structured justification scoring improved prescribing behavior across multiple indications, including respiratory tract infection.

**How do I explain a no-antibiotic recommendation to a referring veterinarian or specialist?**

Frame the decision around the bacterial threshold concept: the patient's clinical signs do not currently indicate active bacterial infection, and antimicrobials would add risk without benefit. State what you are doing instead, such as antiviral supportive care, nebulisation, or recheck in 48 hours. Offer to revisit the decision if fever develops, discharge becomes purulent, or radiographic changes appear. This approach aligns with the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) on prudent antimicrobial use. Most colleagues accept a reasoned, documented deferral when it is paired with a concrete monitoring plan and a willingness to escalate if the clinical picture changes.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Indications for the use of highest priority critically important antimicrobials in the veterinary sector.](https://pubmed.ncbi.nlm.nih.gov/32240295/). 2020.
- [Antimicrobial use for selected diseases in cats in Switzerland.](https://pubmed.ncbi.nlm.nih.gov/30871537/). 2019.
- [Antimicrobial prescriptions in cats in Switzerland before and after the introduction of an online antimicrobial stewardship tool.](https://pubmed.ncbi.nlm.nih.gov/32620170/). 2020.
- [Effect of antimicrobial stewardship on antimicrobial prescriptions for selected diseases of dogs in Switzerland.](https://pubmed.ncbi.nlm.nih.gov/33112451/). 2020.
- [Association between antimicrobial drug class for treatment and retreatment of bovine respiratory disease (BRD) and frequency of resistant BRD pathogen isolation from veterinary diagnostic laboratory samples.](https://pubmed.ncbi.nlm.nih.gov/31835273/). 2019.
- [Use of cefovecin in a UK population of cats attending first-opinion practices as recorded in electronic health records.](https://pubmed.ncbi.nlm.nih.gov/27507842/). 2017.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Antimicrobial Stewardship in Urinary Tract Infections of Dogs and Cats](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-urinary-tract-infections-dogs-cats)
- [Antimicrobial Stewardship in Feline Respiratory Infections: When Antibiotics Are Needed](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-feline-respiratory)
- [Antimicrobial Stewardship in Canine Postoperative Infections: Prevention and Treatment](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-postoperative)
- [Antimicrobial Stewardship in Equine Respiratory Disease: Evidence-Based Use](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-equine-respiratory-disease-evidence-based)
- [Antimicrobial Stewardship in Feline Urinary Tract Infections: When to Treat and When to Wait](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-feline-uti)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.